Prostate Cancer Vaccine Candidate Limited Disease Progression
ProscaVax prostate cancer vaccine candidate limited cancer progression in 80% of patients
A new prostate cancer vaccine, ProscaVax, limited cancer progression in 80% of patients during a Phase 1 clinical trial.
Data from this small study confirms there were no drug-related serious adverse events or dose-limiting toxicities resulting from ProscaVax vaccination.
Additionally, this study’s results suggest a durable response 31 weeks post-therapy.
In this Phase 1 clinical trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing prostate-specific antigen (PSA) were treated with 6 intradermal injections of ProscaVax.
ProscaVax cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and completed the first follow-up at 19 weeks, with 16 of 20 patients (80%) demonstrating stable disease/no prostate cancer progression. The definition of progression was based on blood tests and xrays.
Only 4 patients' cancer progressed during ProscaVax therapy.
Dr. Jonathan Head, Chief Executive Officer at OncBioMune said, “Now, we have to expand the therapeutic range and increase the number of patients enrolled in mid-stage research, but the data to date certainly is encouraging to provide a safe and effective treatment for the millions of men battling prostate cancer today.”
Prostate cancer is the most common non-skin cancer among American men. It is the second leading cause of death from cancer in men.
Most men with prostate cancer are older than 65 years and do not die from the disease.
Almost all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids).
Prostate cancer often has no early symptoms. Advanced prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions.
There is not an approved vaccine for the prevention of prostate cancer, according to the Centers for Disease Control and Prevention.
OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to attack tumor cells without damaging healthy tissue. Andrew Kucharchuk, President and Chief Financial Officer.
- OncBioMune Meets Primary Objective in Trial of ProscaVax Immunotherapy Vaccine for Prostate Cancer
- Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients (PS
- Prostate Cancer
- Prostate Cancer - Patient Version
- 100% of Prostate Cancer Patients Completing 31-Week Post-Therapy Exam After Treatment with OncBioMune Immunotherapy Show No Dise